Alba Therapeutics Corp.
This article was originally published in Start Up
Executive Summary
Alba Therapeutics has identified the pathway and a key protein associated with paracellular permeability, which is impaired in autoimmune diseases. It is testing an antagonist of that protein as a therapy for celiac disease and eventually, type 1 diabetes.